FDA Drops Plans For Follow-On Biologics Policy
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency does not plan to release documents or announce policies concerning follow-on proteins "in the near future," Deputy Commissioner Gottlieb says.
You may also be interested in...
Follow-On Biologics White Paper From FDA Could Be Delayed Until Fall
Policy implementation is likely to require agency action before legislative initiatives, according to Reed Smith attorney Deborah Shelton.
FDA Follow-on Proteins Draft Guidance Will Be Followed By Third Public Meeting
The agency's next step on "generic" biologics is to release a background document on FDA's past regulatory and scientific treatment of protein products. The draft guidance – which could be a set of "interlocking" guidances – will be released subsequent to the background document.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter